

THURSDAY, 21 SEPTEMBER 2023

GOLD INDUSTRY-SUPPORTED SYMPOSIUM – HELSINN HEALTHCARE SA

(not part of main CME programme)

OBJECTIVES

To present the data available regarding the potential of chlormethine gel to modify the tumour microenvironment in mycosis fungoides (MF), and to discuss the ongoing “Deep phenotyping of CTCL, type mycosis fungoides” IIS trial and its preliminary results.

PROGRAMME

Chlormethine gel and tumour microenvironment modification in mycosis fungoides: a concept or an evidence-based reality?

13:00 – 13:02 **Opening and welcome**

Maarten Vermeer, Leiden University Medical Center, Leiden, the Netherlands

13:02 – 13:10 **Disease modification concept: preliminary evidence**

Emmanuella Guenova, Lausanne University Hospital CHUV, Lausanne, Switzerland

13:10 – 13:25 **Deep phenotyping of CTCL, type mycosis fungoides**

Maarten Vermeer

13:25 – 13:30 **Interactive Q&A session and closing remarks**

Moderated by both speakers

Closing by Maarten Vermeer

FRIDAY, 22 SEPTEMBER 2023

GOLD INDUSTRY-SUPPORTED SYMPOSIUM – THERAKOS/MALLINCKRODT

(not part of main CME programme)

PROGRAMME

Time to Next Treatment and Extracorporeal Photopheresis-containing treatment regimens in the management of Cutaneous T-Cell Lymphoma

08:30 – 08:55 Julia Scarisbrick, University Hospital Birmingham, Birmingham, United Kingdom

08:55 – 09:00 Closing remarks

FRIDAY, 22 SEPTEMBER 2023

DIAMOND INDUSTRY-SUPPORTED SYMPOSIUM – KYOWA KIRIN

(not part of main CME programme)

With a shared aim of making a difference to the lives of people with cutaneous T-cell lymphoma (CTCL), we invite you to join this promotional Kyowa Kirin-sponsored symposium that will explore **the connections between CTCL symptoms and quality of life (QoL)**.

PROGRAMME

The power of connection. Connecting symptoms to quality of life: the importance of considering patient wellbeing when managing CTCL.

13:15 – 13:20 **Welcome and introduction**

Maarten Vermeer, Leiden University Medical Center, Leiden, the Netherlands

13:20 – 13:30 **What are patient perspectives on how CTCL affects their QoL?**

Susan Thornton, Patient advocacy group representative from the Cutaneous Lymphoma Foundation

13:30 – 13:45 **Understanding the connection between CTCL symptoms and QoL outcomes**

Kevin Molloy, Trinity College, Dublin, Ireland

13:45 – 14:00 **The latest RWE and clinical experience on the use of POTEIGEO®▼ (mogamulizumab)**

Chalid Assaf, Helios Klinikum Krefeld, Krefeld, Germany

14:00 – 14:15 **Q&A and meeting close**

Maarten Vermeer, Leiden University Medical Center, Leiden, the Netherlands
All faculty discussion